Recruiting studies: Mgmt Methylated Glioblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Phase 3 · 20 location(s) · Vastra Gotaland Region · NCT06419946 DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Phase 1/Phase 2 · 5 location(s) · University of California, San Francisco · NCT06504381 Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Phase 2 · 1 location(s) · Baptist Health South Florida · NCT06991101 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Phase 2/Phase 3 · 63 location(s) · Global Coalition for Adaptive Research · NCT03970447 G-CSF After Chemo-radiation in Patients With Glioblastoma
Phase 2 · 1 location(s) · Massachusetts General Hospital · NCT06649851 Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tum
Phase 1/Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT05432804

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.